

Title (en)
LIPOSOMAL FORMULATIONS OF BCL INHIBITORS

Title (de)
LIPOSOMALE FORMULIERUNGEN VON BCL-INHIBITOREN

Title (fr)
FORMULATIONS LIPOSOMALES D'INHIBITEURS DE BCL

Publication
EP 4370098 A1 20240522 (EN)

Application
EP 22842954 A 20220715

Priority

- US 202163222887 P 20210716
- US 2022037371 W 20220715

Abstract (en)
[origin: CA3175913A1] Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.

IPC 8 full level
A61K 9/127 (2006.01); **A61K 9/10** (2006.01); **A61K 31/00** (2006.01); **A61K 31/015** (2006.01)

CPC (source: EP IL KR)
A61K 9/1272 (2013.01 - EP IL KR); **A61K 31/12** (2013.01 - KR); **A61K 31/496** (2013.01 - KR); **A61K 31/635** (2013.01 - EP IL KR); **A61K 45/06** (2013.01 - EP IL KR); **A61K 47/02** (2013.01 - KR); **A61K 47/186** (2013.01 - IL); **A61K 47/20** (2013.01 - IL); **A61K 47/24** (2013.01 - KR); **A61K 47/26** (2013.01 - IL); **A61K 47/28** (2013.01 - IL); **A61P 7/04** (2018.01 - IL); **A61P 35/00** (2018.01 - EP IL KR); **A61P 35/02** (2018.01 - KR); **A61K 2300/00** (2013.01 - KR)

C-Set (source: EP)
A61K 31/635 + A61K 2300/00

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
AU 2022312484 A1 20240215; CA 3175913 A1 20230116; CN 117897139 A 20240416; EP 4370098 A1 20240522; IL 310159 A 20240301; KR 20240037264 A 20240321

DOCDB simple family (application)
AU 2022312484 A 20220715; CA 3175913 A 20220715; CN 202280059249 A 20220715; EP 22842954 A 20220715; IL 31015924 A 20240115; KR 20247004242 A 20220715